Pulmatrix, Inc. 8K

Pulmatrix announced Q2 2026 results, detailed its strategy to monetize its clinical assets, and updated investors on progress toward closing its merger with Eos SENOLYTIX, including the filing of a Form S-4 and earlier $1.0 million preferred stock financing with an Eos affiliate.

Pulmatrix, Inc. reported its second quarter 2026 financial results and provided an update on its previously announced merger with Eos SENOLYTIX, highlighting the filing of a Form S-4 related to the merger, the expectation that the transaction will close in the third quarter of 2026 subject to customary conditions, and the prior $1.0 million private placement of Series B Convertible Preferred Stock with an Eos affiliate. The company emphasized that all internal clinical development is currently on hold as it seeks to out‑license or monetize its iSPERSE‑based clinical assets (including PUR1900, PUR3100, and PUR1800), while its partner Cipla advances PUR1900 into a Phase 3 trial in India and Pulmatrix retains royalty and U.S. co‑rights. Financially, Pulmatrix reported minimal R&D spending, reduced G&A expenses, a net loss of $1.0 million for the quarter, cash and cash equivalents of $2.2 million plus $0.7 million in restricted cash as of June 30, 2026, and noted that its financial statements include a going concern assumption but that its cash is expected to fund operations at least through the anticipated merger closing.

Filing Facts

CIK

1574235

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-037592

Alert Tier

7